inside tracker
inside tracker

Drugs

Longevity companies to watch in 2021

As the world enters the new year with a vaccine and an increased focus on geroprotection, there’s much to look forward to. Research from the...

A year in Longevity: progress perspectives

2020's journey to extending healthy human Longevity. The journey to Longevity has many stages, whether it's a clinical pipeline, gaining regulatory approval for a drug,...

A year in Longevity: different perspectives

Looking for anti-aging solutions in some unusual places. 2020 has seen Longevity.Technology covering a variety of news in the Longevity sector, from discoveries in the...

A year in Longevity: founders’ perspectives

Speaking to the innovators behind some of Longevity’s most exciting companies. Continuing our look back at some of the highlights of 2020, we thought we’d...

A year in Longevity: science perspectives

Longevity leaders on the key issues facing our sector. Over the past year, we’ve had the pleasure of speaking to some of the Longevity sector’s...

VC and drug developer scale-up their incubator model

Collaboration set to establish new ventures for drug discovery and development and advance UCSF discoveries to patients. Autobahn Labs has announced a strategic collaboration with...

Longevity biomarker firm to align CROs, pharma and consumers

Cerascreen expands from consumer biomarker testing into clinical trial recruitment and discovery of Longevity compounds. Combining a wide range of consumer biomarker testing kits with...

Eliminating senescent cells to improve heart attack recovery

A drug that exterminates senescent cells improves recovery after a heart attack, according to new research, and could pave the way for a new...

NAD boosting to reverse senescence and inflammaging

Senescent cells promote NAD tissue decline during aging through CD38 enzymes which can now become a novel therapeutic target. Nicotinamide adenine dinucleotide (NAD) is a...

Sigilon IPO raises $145m to address chronic diseases

Sigilon boosts its human cell therapeutics pipeline through IPO. Sigilon Therapeutics, Inc, a biotech seeking to develop functional cures for chronic diseases through its Shielded...

Deep Longevity reveals highly-accurate aging clock

Epigenetic aging clock DeepMAge has 3-year error margin and could be the most accurate DNA methylation clock to date. Deep Longevity, the Hong-Kong based Longevity...

Calico’s memory-enhancing drug reverses age-related mental decline

UCSF study shows Calico-licensed small molecule cognitive enhancer ISRIB reverses age-related memory decline in mice within days. ISRIB (integrated stress response inhibitor) is an experimental...

BioAge CEO: “It’s all about the data.”

BioAge's Kristen Fortney explains how focusing on human data will see two age-targeting drugs head to the clinic next year. Yesterday, the world again sat...

Silicon Valley is waking up to Longevity and senolytics

Silicon Valley's Rubedo Life Sciences closes $12m seed round for proprietary drug discovery platform that targets senolytics. Following-on from BioAge's funding announcement another biotech start-up...

BioAge lands $90 million; gears up for clinical trials in 2021

Company also appoints Chief Medical Officer as it prepares to enter the clinic with two Phase 2-ready therapeutic compounds that target aging pathways. Longevity biotech...

Viral vector start-up aims to tackle gene therapy Longevity bottleneck

64x Bio will use proprietary platform to spearhead cell and gene therapy manufacture. Gene therapy can be a fantastic tool for targeting chronic age-related conditions;...

Defining Alzheimer’s by biomarkers could improve clinical trials

Incorporating biomarkers into the research definition of Alzheimer's disease should lead to delayed progression, better treatment and new criteria for clinical trials. When we think...

Biotech Elevian announces $15m equity financing

The anti-aging company looks to the clinic with Prime Movers Lab leading the round. Massachusets-based Elevian announced this week that it had closed $15 million equity...

Targeting inflammaging: the hidden “inflammapath” inside us

Keystone Bio seeks funding as it gears up for clinical trials of therapeutic targeting the “keystone pathogen” of chronic inflammaging. Lurking in the mouths of...

Found: the missing link in the Longevity ‘supply-chain’

Co-founder of new Longevity course for physicians reveals plans to expand the program to science students and, ultimately, everyone. Following yesterday’s news about the launch...
inside tracker
lumen

Latest articles